Rochelle Cunningham, MD
Nephrology · Towson, MDNPI 1508815887
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (59.7%), food and beverage and education — rather than concentrated in one kind of arrangement. Vertex accounts for 60.5% of it on its own, with 19 other manufacturers making up the rest. 2025 is the largest year on record at $4,048, more than ten times the $299 reported in 2019.
Across 70 payments — averaging $84.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Vertex$4K
- AstraZeneca$272
- Boehringer Ingelheim$269
- Amgen$259
- Novartis$213
- Bayer$182
- plus $1K from 14 others
What the payments were for
- Consulting fees$3,54360%
- Food & beverage$2,31339%
- Education$761%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Vertex | 7 | $3,588 |
| AstraZeneca | 5 | $272 |
| Boehringer Ingelheim | 8 | $269 |
| Amgen(2 entities) | 3 | $259 |
| Novartis | 7 | $213 |
| Bayer | 4 | $182 |
| Novo Nordisk | 3 | $159 |
| Mallinckrodt Hospital Products Inc. | 2 | $138 |
| GSK | 2 | $127 |
| Calliditas Therapeutics US Inc. | 1 | $125 |
| Akebia Therapeutics Inc | 7 | $121 |
| Aurinia Pharma U.S., Inc. | 1 | $120 |
| Vifor Pharma, Inc. | 1 | $102 |
| Pfizer | 2 | $95 |
| Travere Therapeutics, Inc. | 12 | $44 |
| AbbVie | 1 | $33 |
| Biogen | 1 | $28 |
| Lilly USA, LLC | 1 | $27 |
| Ardelyx, Inc. | 1 | $20 |
| Otsuka America Pharmaceutical, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,932 in reported general payments places this provider in the 85th percentile of 285 nephrology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VeltassaPatiromer Calcium Sorbitex | 28 | $40,002 |
| FarxigaDapagliflozin Propanediol | 39 | $36,368 |
| JardianceEmpagliflozin | 56 | $34,354 |
| KerendiaFinerenone | 43 | $30,398 |
| Calcitriol | 181 | $2,745 |
| Nifedipine ErNifedipine | 67 | $1,925 |
| Labetalol Hcl | 20 | $906 |
| Losartan Potassium | 66 | $699 |
| Potassium Chloride | 38 | $487 |
| Colchicine | 17 | $479 |
| Lisinopril | 42 | $368 |
| Metoprolol Succinate | 24 | $366 |
| Chlorthalidone | 13 | $316 |
| Famotidine | 18 | $295 |
| Bumetanide | 13 | $268 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $272 | $36,36839 claims |
| Boehringer IngelheimJardiance | $269 | $34,35456 claims |
| BayerKerendia | $182 | $30,39843 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 285 nephrology providers in Maryland.
Other nephrology in Towson
- Kiran SamindlaFrederick$491K
- Matthew WeirBaltimore$490K
- Chirag ParikhBaltimore$186K
- Mohamad HanounehBaltimore$174K
- Daniel BrennanBaltimore$133K
- Monika DhillonBaltimore$126K
- Duvuru GeethaBaltimore$91K
- Eli RozaHagerstown$79K
- Mohamed AttaBaltimore$65K
- Michelle EstrellaBaltimore$55K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.